Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in relation to stage of disease, 1993–2003
Open Access
- 6 June 2006
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 95 (1) , 91-95
- https://doi.org/10.1038/sj.bjc.6603216
Abstract
The aim of this study was to investigate recent trends in incidence, mortality and survival in patients diagnosed with malignant melanoma (MM) in relation to stage (Breslow thickness). Cases of primary invasive and in situ MM diagnosed between 1st January 1993 and 31st December 2003 in the former Yorkshire Health Authority were identified from cancer registry data. Over the study period, the incidence of invasive MM increased from 5.4 to 9.7 per 100 000 in male subjects and from 7.5 to 13.1 per 100 000 in female subjects. Most of this increase was seen in thin tumours (In situ melanoma rates increased only slightly. Over the same time period, mortality rates have been relatively constant in both male and female subjects. Five-year relative survival varied from 91.8% (95% CI 90.4–93.1) for patients with thin tumours to 41.5% (95% CI 36.7–46.3) for those with thick tumours. In multivariable analyses, Breslow thickness was the most important prognostic factor. Age, sex and level of deprivation were also identified as independent prognostic factors. The trends in incidence suggest that the increase is real, rather than an artefact of increased scrutiny, implying that primary prevention in the Yorkshire area of the UK has failed to control trends in incidence. Mortality, in contrast, appears to be levelling off, indicating that secondary prevention has been more effective.Keywords
This publication has 37 references indexed in Scilit:
- Using RNA sample titrations to assess microarray platform performance and normalization techniquesNature Biotechnology, 2006
- OAZ Regulates Bone Morphogenetic Protein Signaling through Smad6 ActivationJournal of Biological Chemistry, 2006
- Comparison of Affymetrix GeneChip expression measuresBioinformatics, 2006
- Melanoma incidence has risen in EuropeBMJ, 2005
- Cutaneous malignant melanoma in EuropeEuropean Journal Of Cancer, 2004
- Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3Cancer Letters, 2004
- Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in ScandinaviaInternational Journal of Cancer, 2003
- Host Prostaglandin E2-EP3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor GrowthThe Journal of Experimental Medicine, 2003
- Transcription Mapping of the 5q− Syndrome Critical Region: Cloning of Two Novel Genes and Sequencing, Expression, and Mapping of a Further Six Novel cDNAsGenomics, 2000
- The melanoma epidemic. Is increased surveillance the solution or the problem?Archives of Dermatology, 1996